NASDAQ:CBAY

CymaBay Therapeutics Stock Forecast, Price & News

$4.76
-0.14 (-2.86 %)
(As of 06/15/2021 12:08 PM ET)
Add
Compare
Today's Range
$4.73
$4.94
50-Day Range
$3.94
$4.90
52-Week Range
$3.16
$9.06
Volume20,437 shs
Average Volume813,713 shs
Market Capitalization$328.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24
30 days | 90 days | 365 days | Advanced Chart
Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


CymaBay Therapeutics logo

About CymaBay Therapeutics

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.77 out of 5 stars

Medical Sector

220th out of 2,100 stocks

Pharmaceutical Preparations Industry

106th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

Is CymaBay Therapeutics a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CymaBay Therapeutics stock.
View analyst ratings for CymaBay Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than CymaBay Therapeutics?

Wall Street analysts have given CymaBay Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CymaBay Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for CymaBay Therapeutics
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced its quarterly earnings data on Thursday, May, 13th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.01.
View CymaBay Therapeutics' earnings history
.

How has CymaBay Therapeutics' stock price been impacted by COVID-19?

CymaBay Therapeutics' stock was trading at $1.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CBAY stock has increased by 215.6% and is now trading at $4.86.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CBAY?

11 analysts have issued 1-year target prices for CymaBay Therapeutics' shares. Their forecasts range from $7.00 to $14.00. On average, they expect CymaBay Therapeutics' share price to reach $10.92 in the next twelve months. This suggests a possible upside of 124.6% from the stock's current price.
View analysts' price targets for CymaBay Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the following people:
  • Mr. Sujal A. Shah, Pres, CEO & Director (Age 48, Pay $820.57k)
  • Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 66, Pay $597.89k)
  • Mr. Paul T. Quinlan, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 58, Pay $578.82k)
  • Mr. Daniel Menold, VP of Fin. (Age 51)
  • Mr. Ken Boehm, Sr. VP of HR
  • Mr. Patrick J. O'Mara, Sr. VP of Bus. Devel. (Age 60)
  • Dr. Robert L. Martin, Sr. VP of Manufacturing & Nonclinical Devel. (Age 59)
  • Ms. Klara A. Dickinson-Eason, Chief Regulatory & Quality Assurance Officer (Age 53)
  • Ms. Becki Filice, Sr. VP of Portfolio & Product Leadership (Age 60)

Who are some of CymaBay Therapeutics' key competitors?

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.64%), Baker BROS. Advisors LP (3.15%), Dimensional Fund Advisors LP (1.92%), Geode Capital Management LLC (1.68%), D. E. Shaw & Co. Inc. (1.39%) and Renaissance Technologies LLC (1.29%).
View institutional ownership trends for CymaBay Therapeutics
.

Which institutional investors are selling CymaBay Therapeutics stock?

CBAY stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Baker BROS. Advisors LP, D. E. Shaw & Co. Inc., Squarepoint Ops LLC, Citigroup Inc., Strs Ohio, Northern Trust Corp, and Acuta Capital Partners LLC.
View insider buying and selling activity for CymaBay Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying CymaBay Therapeutics stock?

CBAY stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, DAFNA Capital Management LLC, CM Management LLC, Occudo Quantitative Strategies LP, Geode Capital Management LLC, Massachusetts Financial Services Co. MA, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for CymaBay Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $4.86.

How much money does CymaBay Therapeutics make?

CymaBay Therapeutics has a market capitalization of $335.34 million. The biopharmaceutical company earns $-50,990,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How many employees does CymaBay Therapeutics have?

CymaBay Therapeutics employs 41 workers across the globe.

What is CymaBay Therapeutics' official website?

The official website for CymaBay Therapeutics is www.cymabay.com.

Where are CymaBay Therapeutics' headquarters?

CymaBay Therapeutics is headquartered at 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]


This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.